Form 4: Guardant Health CFO's RSU Vesting and Tax Sale

Guardant Health CFO Michael Brian Bell reported the vesting of restricted stock units, leading to an increase in common stock holdings and a sale of shares for tax obligations.

Summary

• Chief Financial Officer Michael Brian Bell reported transactions on September 15, 2025, involving Guardant Health, Inc. common stock and restricted stock units (RSUs).
• 1,233 Restricted Stock Units (RSUs) from a May 9, 2022 grant vested and converted into common stock.
• An additional 2,039 RSUs from a June 9, 2023 grant also vested and converted into common stock.
• A total of 3,272 shares of common stock were acquired through the vesting of these RSUs.
• 1,659 shares of common stock were disposed of at a price of $54.79 per share to cover tax withholding obligations associated with the RSU vesting.
• Following these transactions, Michael Brian Bell directly owns 44,641 shares of Guardant Health common stock.
• He also holds 2,466 unvested RSUs from the May 9, 2022 grant and 6,117 unvested RSUs from the June 9, 2023 grant.

Sentiment

Score: 5

Explanation: This is a routine insider transaction report (Form 4) detailing RSU vesting and a subsequent tax-related share sale. It reflects standard executive compensation practices and does not indicate significant positive or negative operational or financial news for the company, thus having a neutral sentiment.

Positives

• The vesting of Restricted Stock Units indicates continued executive compensation and retention, aligning management interests with shareholder value.
• A net increase of 1,613 shares in direct common stock holdings for the CFO (3,272 shares acquired from vesting minus 1,659 shares sold for tax withholding).

Negatives

• 1,659 shares were sold to cover tax withholding obligations, which, while standard, reduces the direct share count.

Future Outlook

The remaining 75% of the May 9, 2022 RSU award is scheduled to vest in equal quarterly installments over the three-year period following March 15, 2023. The remaining 67% of the June 9, 2023 RSU award is scheduled to vest in equal quarterly installments over the two-year period following June 15, 2024.

Industry Context

This filing is a routine insider transaction report (Form 4) and does not provide specific insights into broader industry trends or competitive landscape. It primarily details executive compensation and ownership changes.

Stakeholder Impact

• Shareholders: Reflects routine executive compensation and changes in insider ownership, which is generally neutral for stock price unless the scale is unusually large or unexpected.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Next Steps

• Continued vesting of the remaining Restricted Stock Units for Michael Brian Bell according to the established schedules.

Key Dates

Recommendation

This Form 4 details a routine vesting of restricted stock units and a subsequent sale of shares to cover tax obligations by the Chief Financial Officer. Such transactions are standard components of executive compensation and do not typically signal a change in the company's fundamental outlook or performance. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Guardant Health, GH, Michael Brian Bell, CFO, Form 4, SEC filing, insider transaction, restricted stock units, RSU vesting, stock ownership, tax withholding